Maia Fertility

Maia Fertility is a private biotechnology company focused on improving fertility and embryo implantation outcomes in both human assisted reproduction and veterinary reproduction. The company is developing Ferizyme, a proprietary sustained-release enzyme platform designed to remodel the uterine extracellular matrix and improve implantation success. Its lead commercial near-term focus appears to be cattle fertility, while it is also positioning the platform for future human IVF applications. Maia Fertility presents itself as a reproductive health innovator based in Rehovot, Israel, and is led by CEO Nir Arbel. Recent funding from Mercantile Life Science Ventures IV and Big Idea Ventures is intended to support commercial-farm clinical studies in North America and Europe and further optimize the delivery technology.